Literature DB >> 24430762

Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

Choli Hartono1, Miriam Chung, Sheng F Kuo, Surya V Seshan, Thangamani Muthukumar.   

Abstract

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The nephrotic syndrome due to idiopathic membranous nephropathy is often resistant to glucocorticosteroids and requires an alkylating agent such as chlorambucil or cyclophosphamide to induce remission. Recent studies illustrate that antibodies against the autoantigen M-type phospholipase A2 receptor contribute to a vast majority but not all cases of idiopathic membranous nephropathy. Herein, we report a patient with nephrotic syndrome due to membranous nephropathy that was resistant to 6 months of therapy with ramipril and high-dose glucocorticosteroids but responded to a single cycle of bortezomib infusion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430762      PMCID: PMC3966568          DOI: 10.1007/s40620-013-0028-x

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  12 in total

1.  Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.

Authors:  Corrado Murtas; Maurizio Bruschi; Giovanni Candiano; Gabriella Moroni; Riccardo Magistroni; Andrea Magnano; Francesca Bruno; Antonella Radice; Luciana Furci; Lucia Argentiero; Maria Luisa Carnevali; Piergiorgio Messa; Francesco Scolari; Renato Alberto Sinico; Loreto Gesualdo; Fernando C Fervenza; Landino Allegri; Pietro Ravani; Gian Marco Ghiggeri
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 8.237

2.  IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence.

Authors:  Terje Forslund; Anu Sikiö; Jorma Anttinen
Journal:  Nephrol Dial Transplant       Date:  2007-06-07       Impact factor: 5.992

3.  ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.

Authors:  Jake Shortt; Danielle H Oh; Stephen S Opat
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

4.  Rituximab in idiopathic membranous nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Antonietta Chianca; Annalisa Perna; Barbara Ruggiero; Flavio Gaspari; Alessandro Rambaldi; Maddalena Marasà; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

5.  Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.

Authors:  D C Cattran; Y Pei; C M Greenwood; C Ponticelli; P Passerini; E Honkanen
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

6.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

Authors:  Laurence H Beck; Fernando C Fervenza; David M Beck; Ramon G B Bonegio; Fahim A Malik; Stephen B Erickson; Fernando G Cosio; Daniel C Cattran; David J Salant
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

7.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

Review 8.  Glomerular diseases: membranous nephropathy--a modern view.

Authors:  Claudio Ponticelli; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

9.  Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.

Authors:  D K Perry; J M Burns; H S Pollinger; B P Amiot; J M Gloor; G J Gores; M D Stegall
Journal:  Am J Transplant       Date:  2008-10-31       Impact factor: 8.086

10.  A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini; L Cagnoli; B Cesana; C Pozzi; S Pasquali; E Imbasciati; C Grassi; B Redaelli
Journal:  N Engl J Med       Date:  1989-01-05       Impact factor: 91.245

View more
  10 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 2.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

Review 3.  Treatment of primary membranous nephropathy: where are we now?

Authors:  Andrea Angioi; Nicola Lepori; Ana Coloma López; Sanjeev Sethi; Fernando C Fervenza; Antonello Pani
Journal:  J Nephrol       Date:  2017-09-05       Impact factor: 3.902

Review 4.  Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.

Authors:  Maxime Teisseyre; Marion Cremoni; Sonia Boyer-Suavet; Caroline Ruetsch; Daisy Graça; Vincent L M Esnault; Vesna Brglez; Barbara Seitz-Polski
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 5.  Primary membranous nephropathy: an endless story.

Authors:  Ponticelli Claudio
Journal:  J Nephrol       Date:  2022-10-17       Impact factor: 4.393

6.  A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients.

Authors:  Chiara Cantarelli; Marta Jarque; Andrea Angeletti; Joaquin Manrique; Susan Hartzell; Timothy O'Donnell; Elliot Merritt; Uri Laserson; Laura Perin; Chiara Donadei; Lisa Anderson; Clara Fischman; Emilie Chan; Juliana Draibe; Xavier Fulladosa; Joan Torras; Leonardo V Riella; Gaetano La Manna; Enrico Fiaccadori; Umberto Maggiore; Oriol Bestard; Paolo Cravedi
Journal:  Kidney Int Rep       Date:  2020-08-01

7.  Bortezomib-containing regiment in treating glomerulopathy with fibronectin deposits combined with monoclonal gammopathy of undetermined significance: a case report and literature review.

Authors:  Wenjie Zhang; Qike Zhang; Xiaofang Wei; Youfan Feng
Journal:  Ann Transl Med       Date:  2022-03

8.  The clinicopathological features of patients with membranous nephropathy.

Authors:  Hanyu Zhu; Qiuxia Han; Dong Zhang; Yong Wang; Jing Gao; Xiaoli Yang; Wenjia Geng; Xiangmei Chen
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-18

Review 9.  Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.

Authors:  Jorge Rojas-Rivera; Fernando C Fervenza; Alberto Ortiz
Journal:  Drugs       Date:  2021-12-21       Impact factor: 9.546

Review 10.  B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management.

Authors:  Benjamin Y F So; Desmond Y H Yap; Tak Mao Chan
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.